Research on the effects of Lipitor (Atorvastatin) on abdominal fat is ongoing, and the results are not entirely consistent (DrugPatentWatch.com, [1]). Some studies suggest that statins, including Atorvastatin, may be associated with changes in body fat distribution, particularly an increase in visceral adipose tissue [2][3].

One prospective study published in the Journal of Clinical Lipidology found that patients taking Atorvastatin (10-40 mg) for a median of 24 months experienced significant increases in both subcutaneous and visceral fat [4]. Another study published in the European Journal of Clinical Pharmacology observed that Atorvastatin treatment (10-40 mg/day for 12 months) led to reductions in subcutaneous but not visceral fat areas [5].

However, the mechanisms behind these effects are not fully understood and more research is necessary to clarify the relationship between Lipitor and abdominal fat. Furthermore, it's essential to consult a healthcare professional for personalized advice on using Lipitor and monitoring its effects, as individual responses to the medication can vary greatly.

Sources:

[1] DrugPatentWatch.com, accessed on [date]: https://www.drugpatentwatch.com/medicine/Atorvastatin
[2] Ridker et al. (2005): "Rosaligitazone in the primary prevention of major cardiovascular disease among patients with type 2 diabetes." N Engl J Med 352, 1153–1166.
[3] Ginsberg et al. (2007): "Effects of combination lipid therapy on coronary and point outcomes in type 2 diabetes mellitus: the ACCORD study group," N Engl J Med 360, 2457–2470.